Kala Pharmaceuticals Receives Cystic Fibrosis Foundation Grant
2/5/2013 10:46:32 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, announced today that it has been awarded a grant from the Cystic Fibrosis Foundation to demonstrate that Kala’s Mucosal-Penetrating Products (MPPs) also penetrate bacterial biofilms. Bacteria biofilms attach to respiratory surfaces and aggregate in a matrix that prevents antibiotics from effectively treating the chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients that is linked to morbidity and mortality.
comments powered by